Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 249 | 47 | 199 |
| Samples | 240 | 42 | 195 |
| Peptides | 173 | 33 | 148 |
Function
NKX2-2 · NK2 homeobox 2
The protein encoded by this gene contains a homeobox domain and may be involved in the morphogenesis of the central nervous system. This gene is found on chromosome 20 near NKX2-4, and these two genes appear to be duplicated on chromosome 14 in the form of TITF1 and NKX2-8. The encoded protein is likely to be a nuclear transcription factor. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000377142 | O95096 | 249 | 173 |
Gene Properties
Recurrent Mutations
All 173 amino-acid changes on canonical ENST00000377142 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NKX2-2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NKX2-2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Squamous Cell Lung Carcinoma | 1/57 2% | 14/810 2% |
| Endometrial Carcinoma | 5/42 12% | 6/612 1% |
| Bladder Carcinoma | 1/58 2% | 15/956 2% |
| Colorectal Carcinoma | 8/143 6% | 30/3239 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 14/1390 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Gastric Carcinoma | 4/74 5% | 15/1809 1% |
| Melanoma | 1/210 0% | 18/1899 1% |
| Other Solid Cancers | 3/94 3% | 11/1515 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Esophageal Carcinoma | 0/23 0% | 6/769 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 16/2550 1% |
| Biliary Tract Carcinoma | 3/54 6% | 2/950 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 7/1592 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Hepatocellular Carcinoma | 0/46 0% | 6/2210 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Kidney Carcinoma | 0/85 0% | 4/1862 0% |
| Non-Cancerous | 1/104 1% | 1/830 0% |
| B-Lymphoblastic Leukemia | 4/55 7% | 1/2640 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Breast Carcinoma | 0/144 0% | 4/3264 0% |
| Glioma | 0/52 0% | 2/2127 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
Mutation Distribution
Where NKX2-2 is mutated · all tissues, split by cell line vs tissue
How many mutations in NKX2-2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 21 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 249 mutations in NKX2-2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|